Asthma Treatment Market By Treatment Type (Long-term Control Medications {Inhaled Corticosteroids (ICS), Long-Acting Beta Agonists (LABA), Leukotriene Modifiers, Theophylline, Biologic Therapies} Quick-Relief Medications {Short-Acting Beta Agonists (SABA), Anticholinergics, Systemic Corticosteroids}), By Drug Class (Corticosteroids, Beta-Agonist, Leukotriene Inhibitors, Anticholinergics, Biologics, Mast Cell Stabilizers), By Device Type (Inhalers {Metered-Dose Inhalers (MDI), Dry Powder Inhalers (DPI), Soft Mist Inhalers (SMI)} Nebulizers {Jet Nebulizers, Ultrasonic Nebulizers, Mesh Nebulizers} Autoinjectors and Prefilled Syringes), By Route of Administration (Inhalation, Oral, Injectable, Intravenous), By Severity (Mild Asthma, Moderate Asthma, Severe Asthma), and By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Industry Outlook

The Asthma Treatment market accounted for USD 26.3 Billion in 2024 and is expected to reach USD 45.5 Billion by 2035, growing at a CAGR of around 5.1% between 2025 and 2035. The market for asthma treatment is highly broad and falls in a range of drugs, therapies, and devices. These are treatments to manage and treat asthma, characterized by inflammation and airway narrowing of the respiratory tract. This market can be divided into several drug classes-such as inhaled corticosteroids, beta-agonists, leukotriene inhibitors, anticholinergics, biologics, and mast cell stabilizers-which form the basis of this kind of market. Other advanced delivery systems, including inhalers and nebulizers, along with integration of digital health solutions via mobile apps and telehealth services, are also increasingly becoming a part of asthma treatment. Factors driving the market include an increase in the prevalence of the disease, rising awareness of effective disease management, and constant innovation in treatment alternatives. Ultimately, the asthma treatment market has been necessary for providing millions of individuals living with asthma worldwide an improvement in their quality of life.

Report Scope:

Market Dynamics

• Growing Global Asthma Prevalence is Expected to Drive Demand for Enhanced Treatment Solutions

The increasing prevalence of asthma worldwide presents itself as one of the major drivers in the market for improved treatment outcomes. These have increasingly been coupled with urbanization, air pollution, and changed lifestyles as major causes of this ever-on-rise incidence. Exposure to higher levels of pollutants in urban settings still falls on the dangerous side while, according to the World Health Organization, bringing about a total of 4.2 million deaths annually due to outdoor air pollution, leaving mainly the respiratory health of an individual within its sphere. Studies further indicate that there is a 50% increased risk of asthma development among children from highly polluted regions.

The aggravation is further exacerbated by lifestyle changes CDC reports that the prevalence of obesity coupled with low levels of physical activity has seen approximately 20% of adults being obese and having asthma, too. The Global Initiative for Asthma notes that such economic costs are enormous, with about 300 million people affected worldwide, amounting to a U.S. expenditure of about $81 billion yearly. Such an upward trend points towards the tremendous requirement of innovative management options for asthma, effectively improving health outcomes and reducing associated economic costs.

• Rising Awareness of Asthma Management Boosts Demand for Medications and Adherence Tools

The rising awareness of asthma management is significantly driving demand for medications and adherence tools. Increased education about asthma triggers, symptoms, and treatment options has empowered patients to take an active role in their health. According to the Asthma and Allergy Foundation of America, about 60% of patients who suffer from asthma reported improved knowledge about their condition due to such programs. This means that when a patient is educated, medication compliance increases; there are studies wherein findings revealed that patients who are made aware of their treatment plans are likely to adhere to the same 25% of the previous consistency.

The Centers for Disease Control and Prevention state that through effective self-management, there may be a reduction of up to 50% of hospitalization cases due to asthma. With more educated patients, it increasingly looks for treatments such as medications but also devices, including inhaler spacers and digital apps that support adherence, to increase market growth. In general, this increased awareness constitutes an important step toward improving health results and reducing the burden of the disease on healthcare systems.

• High Costs of Biologics and Advanced Therapies Limit Patient Access and Market Growth

The high costs associated with biologics and advanced therapies pose a significant restraint on patient access and market growth in asthma treatment. Such therapy, typically used for the treatment of severe asthma, can reach up to $30,000 annually per patient. The case is also illustrated through the pricing of Advair, one of the critical asthma drugs, which rose from $316 in 2013 to $496 in 2018. Thus, it indicates that costs related to medication are rising with time. The American Academy of Allergy, Asthma, and Immunology (AAAAI) notes that this leads to high unaffordable prices resulting in non-adherence among nearly 40% of patients since they say they cannot afford their prescribed treatments.

At the same time, the Centers for Medicare & Medicaid Services (CMS) note that this type of nonadherence on cost grounds accounts for higher total healthcare costs since such patients are more likely to end up in hospital emergency rooms and admitted. This kind of financial barrier not only constrains individual patients but also health care systems because untreated asthma can significantly complicate patients. Thus, although many rewarding benefits exist within biologics, a very high price is a limitation to many patients, which in turn affects the growth potential of the asthma treatment market.

• Innovations in Delivery Methods to Enhance Patient Compliance and Treatment Effectiveness

New delivery methods such as inhalable vaccines and nanotechnology offer incredible potential for improvements in enhancing patient compliance and maximizing treatment effects in asthma management. The standard inhaler achieves compliance levels of as low as 50-60%, as documented by the Centers for Disease Control and Prevention (CDC). Comparatively, innovative discoveries, such as inhaled vaccines, could ease the process of administration and increase adherence. Works show that adherence rates are increased almost to 90% when compared to those that include needles.

In addition, nanotechnology is used to target the drug delivery system so that, with less amount, higher levels of absorption can be achieved without unwanted side effects. The NIH concluded the research by determining that nano formulations may offer up to an increase of 10-fold in up to as much as bioavailability over conventional formulations. The market is large because, based on the Global Initiative for Asthma (GINA), 300 million people have asthma. Indeed, investment in research and development towards these advanced delivery methods will directly touch the lives of patients and help improve outcomes. Growth may be well above and beyond the requirements of the asthma treatment market.

• Utilizing Digital Health Technologies and Telemedicine in Asthma Management

The rise of digital health technologies and telemedicine presents a significant opportunity to improve asthma management through enhanced accessibility, patient engagement, and treatment adherence. Geographical barriers are not a concern anymore because telemedicine can easily reach out to patients in underserved or rural areas. According to the American Telemedicine Association, up to 60 million Americans living in those areas may gain enhanced access because of telehealth. In addition, remote monitoring devices and mobile health applications enable continuous monitoring of symptoms and medication usage.

According to studies, these technologies have users reduce their asthma-related emergency visits by 30%. Patients are also able to use educational tools and access providers in real-time through the use of these technologies, thereby becoming more adherent to their care plans. Telemedicine is also a lower-cost option than office-based practice. Overall, telemedicine can help bring down healthcare costs as it minimizes unnecessary hospitalizations, whereas the relationship of the physician with the patient increases accessibility to health services. In general, digital health solutions can improve the care of asthma in patients by its integration into patient care and enhance health outcomes and quality of life of patients.

Industry Experts Opinion

"Asthma is quite common in children. It is estimated [globally] that one in ten children have asthma, and in adults, the prevalence is less than in children."

• Dr Ahmed Ismail Manjra, a paediatrician and allergologist at the Allergy and Asthma Centre

Segment Analysis 

Based on treatment type, the asthma treatment market is divided into Long-term Control Medications and Quick-Relief Medications. Long-term Control Medications and Quick-Relief Medications. Further, Long-term Control Medications are usually sub-divided into Inhaled Corticosteroids, Long-Acting Beta Agonists, Leukotriene Modifiers, Theophylline, and biological therapies that work to control inflammation and prevent asthma events. While Quick-Relief Medications consist of SABA, Anticholinergics, and Systemic Corticosteroids that help deliver instant relief during asthma attacks, it is only by acquiring the knowledge on proper usage of the various drugs that it is possible to manage asthma accordingly and thus present a better outlook on patient care.

Based on their mechanisms and therapeutic roles, asthma management treatment encompasses several important classes of drugs. Corticosteroids reduce airway inflammation. Common agents include fluticasone and budesonide. Beta-agonists: These drugs can be divided into two subgroups. The primary drug in the Short Acting (SABA) group for quick relief is albuterol; this is sustained by the Long-Acting (LABA) subgroup with an agent like salmeterol. Leukotriene Inhibitors include substances such as montelukast, which inhibit substances that provoke asthma. Anticholinergics, such as ipratropium, are excellent bronchodilators that open the airways. Biologics, including omalizumab and dupilumab, target particular pathways for the immune system in a patient with severe asthma. Lastly, Mast Cell Stabilizers, like cromolyn sodium, prevent the release of inflammatory mediators. These, together, comprise a holistic approach to asthma management tailored to the unique needs of patients.

Regional Analysis

The North American asthma treatment market is dominated by a robust healthcare infrastructure coupled with a high prevalence of asthma and significant investments in research and development. Nearly 28 million people in the U.S. suffer from asthma, which translates into about 1 in 12 individuals. Of these, nearly 23 million U.S. adults aged 18 and older suffer from it, based on CDC estimates. The hold of innovative therapies, such as biologics and advanced inhalation devices, is thus improving the treatment options delivered to severe asthma patients. This awareness campaign plus education on asthma control is further advancing medication adherence. The presence of major pharmaceutical companies besides ongoing clinical trials implies that treatments are being completed and moved forward. Moreover, the integration of telehealth and digital health technologies will continue to shape care delivery in various ways by supporting higher patient engagement and also access to care. The overall growth of the North American market is thus expected, while technological innovation coupled with a focus on personalized medicine would propel the management of asthma.

The Asia-Pacific asthma treatment market is growing at a tremendous rate, with a very high prevalence of asthma cases reported in the region, with about 262.41 million cases in 2019. This counts for about 45.7 million adults out of the population of China alone, showing the great burden of the condition in the region. India and Japan have also accounted for massive shares of the market, and this can be attributed to rising urbanization, increasing air pollution, and changing lifestyles. More recently, there has been a strong shift towards advanced therapies, among which are biologics and smart inhalers, for more informed patients on how to control asthma. Healthcare policies and programs by the Government towards achieving improved respiratory health increase the availability of treatments. Even further, digital health technologies, such as telehealth, are incorporated into the service for improved patient engagement and adherence. Although access to healthcare is limited and awareness levels vary in different countries, Asia-Pacific can be considered a profitable market for asthma solutions, with particular emphasis placed on innovative solutions that would assist in dealing with the increasing burden of asthma.

Competitive Landscape

The Major players within the asthma treatment market are GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Novartis, and Teva Pharmaceuticals. GlaxoSmithKline is highly specialized in its availability of inhaled corticosteroids, has been working with Thermo Fisher Scientific, which has upgraded inhalation therapies, and has established meaningful relationships with patients through enhanced digital health capabilities and solutions. Boehringer Ingelheim enhanced its inhalation technologies by partnering with the University of Texas. Novartis is coming up with a host of new innovative biologics, has merged with a tech firm to develop AI-based drug discovery, and so on. Teva Pharmaceuticals produces a comprehensive portfolio of drugs, and under strategic partnerships, it's trying new formulations.

Asthma Treatment Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In May 2024, AstraZeneca unveiled its latest research at the ATS 2024 conference, highlighting advancements in respiratory and immune-mediated diseases. The presentation emphasized the strength of its diverse pipeline, focusing on innovative therapies for asthma and related conditions.

• In March 2023, Teva Pharmaceuticals, headquartered in Israel, collaborated with Rimidi to start a respiratory patient monitoring program at Desert Oasis Healthcare in California, utilizing data from Teva's Digihaler System.

Report Coverage:

By Treatment Type

• Long-term Control Medications
  • Inhaled Corticosteroids (ICS)
  • Long-Acting Beta Agonists (LABA)
  • Leukotriene Modifiers
  • Theophylline
  • Biologic Therapies
• Quick-Relief Medications
  • Short-Acting Beta Agonists (SABA)
  • Anticholinergics
  • Systemic Corticosteroids

By Drug Class

• Corticosteroids
• Beta-Agonist
• Leukotriene Inhibitors
• Anticholinergics
• Biologics
• Mast Cell Stabilizers

By Device Type

• Inhalers
  • Metered-Dose Inhalers (MDI)
  • Dry Powder Inhalers (DPI)
• Nebulizers
  • Jet Nebulizers
  • Ultrasonic Nebulizers
  • Mesh Nebulizers
• Soft Mist Inhalers (SMI)
• Autoinjectors and Prefilled Syringes

By Route of Administration

• Inhalation
• Oral
• Injectable
• Intravenous

By Severity

• Mild Asthma
• Moderate Asthma
• Severe Asthma

By Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of the Middle East & Africa

List of Companies:

• GlaxoSmithKline
• AstraZeneca
• Boehringer Ingelheim
• Novartis
• Teva Pharmaceuticals
• Merck & Co.
• Roche
• Sanofi
• Johnson & Johnson
• Pfizer
• AbbVie
• Mylan
• Eli Lilly
• Gilead Sciences
• Horizon Therapeutics

Frequently Asked Questions (FAQs)